

Pyridazine and its related compounds. Part 36. Synthesis and antimicrobial activity of some novel pyrimido[4',5':4,5]thieno[2,3-c]pyridazine derivatives

Ali Deeb · Sebaey Mahgoub

Received: 30 September 2013 / Accepted: 14 April 2014
© Springer Science+Business Media New York 2014

Abstract Novel derivatives of pyrimidothienopyridazine were designed and synthesized through a versatile method. Some of the target compounds bearing the sulfonamide group were evaluated for their antimicrobial activity against representative Gram-positive bacteria, Gram-negative bacteria, and fungi by applying the agar plate diffusion technique. The results showed that derivatives **11a** have promising inhibitory activity against Gram-positive bacteria, and derivatives **11b** and **11e** have also potent inhibition against fungi. Rest of the compounds showed moderate to low activity against the examined microorganisms.

Keywords Thienopyridazine · Pyrimidothienopyridazine · Sulfonamide · Antimicrobial activity

Introduction

Pyridazine and its fused heterocyclic derivatives have recently received much attention from their reactions, synthetic and effective biological importance. It have been reported to possess antimicrobial (Kandile *et al.*, 2009; Asif *et al.*, 2011), antituberculosis (Mangalagiu, 2011 and Mantu *et al.*, 2010), antifungal (Drochioiu *et al.*, 2007), anticancer (Butnariu *et al.*, 2007), herbicidal (Han *et al.*, 2010)

activities, and plant growth regulators and crop protecting agents (Tucaliuc *et al.*, 2008). On the other hand, many fused compounds with thienopyrimidine fragment have received considerable interest because of their remarkable pharmacological properties (Chambhare *et al.*, 2003).

Literature survey reveals that sulfonamides are important class of pharmaceutical compounds exhibiting a wide spectrum of biological activity (Hansch *et al.*, 1990, Connor, 1998 and Hanson *et al.*, 1999), and over 30 drugs containing this functionality are in clinical use, including, antibacterial agents, diuretics, anticonvulsants, hypoglycemic, and HIV protease inhibitors (Kleemann *et al.*, 1999 and Deeb *et al.*, 2014).

In the light of these facts, our interest was focused on synthesizing new heterocyclic compounds including pyrimidothienopyridazine moieties with suitable substituent of biological and pharmacological interest. The structures of the newly synthesized compounds were elucidated on the basis of elemental analysis and various spectroscopic methods and in some cases by comparison with samples previously prepared by unambiguous route. Some of the newly prepared compounds were preliminarily evaluated for their in vitro antibacterial activities against (*Micrococcus luteus* and *Staphylococcus aureus*) as representative examples of Gram-positive bacteria and (*Escherichia coli*) as an example of Gram-negative bacteria. They were evaluated for in vitro antifungal activity against (*Candida albicans*) as representative fungi.

Materials and methods

Chemistry

All melting points were determined in open-glass capillaries and are uncorrected. IR spectra were recorded on a

Taken in part from M.Sc. thesis of Sebaey Mahgoub, Zagazig University, 2013.

A. Deeb (✉) · S. Mahgoub
Department of Chemistry, Faculty of Science, Zagazig
University, Zagazig, Egypt
e-mail: dralideeb@hotmail.com

BRUKER Vector 22 Germany spectrometer (KBr). ^1H -NMR spectra were recorded on Varian Gemini 200 MHz spectrometer and ^{13}C -NMR spectra on JMS-AX500 (125 MHz), using tetramethylsilane as an internal reference. The Electron Impact mass spectra were obtained at 70 eV using Shimadzu QP-2010 Plus mass spectrometer. The reactions were followed up by thin-layer chromatography (TLC) on silica gel F₂₅₄ aluminum sheets (Merck), and the spots were detected by UV lamp at 254–365 nm. The synthesis of ethyl 5-amino-3,4-diphenylthieno[2,3-*c*]pyridazine-6-carboxylate **1** (Deeb *et al.*, 1990) was conducted according to known procedure.

Antimicrobial activity

The antimicrobial activity study was performed using standard cultures of *M. luteus* ATCC10240, *S. aureus* ATCC6538P, *E. coli* ATCC10536, and *C. albicans* ATCC2091. *M. luteus*, *S. aureus*, and *E. coli* cultures were incubated in Nutrient Broth (Difco), while *C. albicans* was incubated in Sabouraud Dextrose Broth (Difco), and dimethylformamide was used as a solvent for tested compounds. A blank disk impregnated with dimethylformamide followed by drying off was used as a negative control. Sulfadoxine, Sulfadimidine, and Nystatin at concentration of 400 $\mu\text{g}/0.1\text{ mL}$ in dimethylformamide were used as positive control.

Preparation of ethyl 5-[(ethoxymethylene)amino]-3,4-diphenylthieno[2,3-*c*]pyridazine-6-carboxylate (**2**)

A stirred mixture of ethyl 5-amino-3,4-diphenylthieno[2,3-*c*]pyridazine-6-carboxylate **1** (1.0 g, 2.6 mmol) in triethyl orthoformate (20 mL) and acetic anhydride (1.0 mL) was refluxed for 6 h. The reaction mixture was evaporated under reduced pressure, and the product **2** was used directly in next steps without further purification.

Preparation of 3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-8(7H)-one (**3**)

A solution of compound **2** (1.0 g, 2.9 mmol) in concentrated ammonium hydroxide solution (20 mL) was stirred at 70 °C for 8 h. The reaction mixture was filtered; the filtrate was neutralized with conc. HCl. The precipitated product was filtered, washed with water and recrystallized from ethanol to give **3**, yellow crystals, yield 48.4 %; mp 188–190 °C; IR (KBr, cm^{-1}): 3165 (NH), 1655 (C=O); MS (m/z , %): 356 [M^+ , 73.03 %], 314 [M^+ -NCO, 87.64 %, F₁], 288 [F₁-HCN, 61.80 %, F₂], 232 [F₂-SCH₂CH₂, 60.67 %, F₃], 205 [F₃-N₂, 60.67 %, F₄]; ^1H -NMR (DMSO-*d*₆): δ (ppm) = 8.8 (*s*, 1H, NH), 7.9 (*s*, 1H, H-6), 7.7–7.4 (*m*, 10H, 2Ph); ^{13}C -NMR (DMSO-*d*₆): δ (ppm): 162.5 (C-

9'), 159.0 (C=O), 155.5 (C-3), 148.3 (C-4''), 144.7 (C-6), 143.3 (C-8'), 135.9 (C-4), 134.5–126.0 (2Ph). Anal. Calcd for C₂₀H₁₂N₄OS (356.4): C, 67.40; H, 3.39; N, 15.72. Found: C, 67.25; H, 3.20; N, 15.55.

Preparation of 8-chloro-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazine (**4**)

A mixture of compound **3** (1.0 g, 2.8 mmol) and phosphoryl chloride (15 mL) was heated at reflux temperature for 4 h. The reaction mixture was cooled and hydrolyzed by addition of crushed ice. The formed precipitate was filtered, washed with water, dried, and recrystallized from ethanol to give **4**, yield 66.6 %, mp 145–147 °C; IR (KBr, cm^{-1}): 1604 (C=N), 1071 (C-Cl); MS (m/z , %): 374 [M^+ , 13.1 %], 315 [M^+ -N = C-Cl, 11.51 %], 57[100 %]; ^1H -NMR (DMSO-*d*₆): δ (ppm) = 8.2 (*s*, 1H, H-6), 7.6–7.3 (*m*, 10H, 2Ph); ^{13}C -NMR (DMSO-*d*₆): δ (ppm): 161.9 (C-4''), 159.3 (C-9'), 156.7 (C-6), 155.5 (C-3), 154.1 (C-Cl), 135.9 (C-4), 134.5–126.3 (2Ph). Anal. Calcd for C₂₀H₁₁ClN₄S (374.8): C, 64.08; H, 2.96; N, 14.95. Found: C, 63.90; H, 2.80; N, 14.85.

Preparation of 7,8-diphenyltetrazolo[1',5':1',6']pyrimido[4',5':4,5]thieno[2,3-*c*]pyridazine (**5**)

A solution of **4** (1.0 g, 2.6 mmol) and sodium azide (0.34 g, 5.2 mmol) in ethanol (25 mL) was refluxed for 4 h. The solvent was evaporated in vacuo, and the residue was washed with water, filtered, dried, and recrystallized from ethanol to give **5**, yellow crystals, yield 89.1 %; mp 248–250 °C; IR (KBr, cm^{-1}): 1635 (C=N); MS (m/z , %): 381 [M^+ , 20.69 %], 357 [M^+ -N₂, 24.14 %, F₁], 327 [F₁-N₂, 21.38 %, F₂]; ^1H -NMR (DMSO-*d*₆): δ (ppm) = 9.2 (*s*, 1H, H-6), 7.7–7.4 (*m*, 10H, 2Ph); ^{13}C -NMR (DMSO-*d*₆): δ (ppm): 161.9 (C-4''), 159.3 (C-9'), 155.5 (C-3), 154.1 (C-Cl), 140.3 (C-6), 135.9 (C-4), 134.5–126.3 (2Ph). Anal. Calcd for C₂₀H₁₁N₇S (381.4): C, 62.98; H, 2.91; N, 25.71. Found: C, 62.83; H, 2.80; N, 25.55.

Preparation of 3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazine-8(7H)-thione (**6**)

A solution of **4** (1.0 g, 2.6 mmol) and thiourea (1.0 g, 1.3 mmol) in ethanol (30 mL) was refluxed for 4 h, the solvent was evaporated on vacuo, and the residue was heated in sodium hydroxide solution (50 mL, 2.5 N) for 30 min and then filtered while hot. The filtrate was cooled and acidified with hydrochloric acid (pH 2), the yellow precipitate obtained was filtered, washed with water, dried, and recrystallized from ethanol to give **6**, yield 80.8 %, mp 230–232 °C; IR (KBr, cm^{-1}): 3390 (NH), 1665 (C=N), 1531 (C=C), 1194 (C=S); MS (m/z , %): 372 [M^+ ,

47.24 %], 85 [100 %]; $^1\text{H-NMR}$ (DMSO- d_6): δ (ppm) = 12.2 (s, 1H, NH), 8.1 (s, 1H, H-6), 7.8–7.4 (m, 10H, 2Ph); $^{13}\text{C-NMR}$ (DMSO- d_6): δ (ppm): 175.7 (C=S), 155.5 (C-3), 152.3 (C-9'), 142.3 (C-6), 138.3 (C-4''), 135.9 (C-4), 133.5–125.3 (2Ph). Anal. Calcd for $\text{C}_{20}\text{H}_{12}\text{N}_4\text{S}_2$ (372.4): C, 64.49; H, 3.25; N, 15.04. Found: C, 64.24; H, 3.09; N, 14.90.

Preparation of 7-amino-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-c]pyridazin-8(7H)-one (7)

To solution of compound **2** (1.0 g, 2.9 mmol) in glacial acetic acid (10 mL), hydrazine hydrate 85 % (2.0 mL, 19.0 mmol) was added. The reaction mixture was refluxed for 8 h, left to cool at room temperature and the precipitated product was filtered, washed with water, and recrystallized from ethanol to give **7**, yellow crystals, yield 34.9 %; mp 180–182 °C; IR (KBr, cm^{-1}): 3414, 3150 (NH₂), 3057 (CH_{arom}), 1676 (C=O), 1594 (C=N); MS (m/z , %): 371 [M^+ , 9.95 %], 342 [$\text{M}^+ - \text{N}_2$, 2.21 %, F₁], 289[F₁-NCO, 1.70 %, F₂], 233 [F₂-CH₂CH₂SH, 3.74 %, F₃], 204 [F₃-N₂, 1.96 %, F₄]; $^1\text{H-NMR}$ (DMSO- d_6): δ (ppm) = 8.1 (s, 1H, H-6), 7.7–7.5 (m, 10H, 2Ph), 2.3 (s, 1H, NH); $^{13}\text{C-NMR}$ (DMSO- d_6): δ (ppm): 162.7 (C-9'), 159.5 (C=O), 155.5 (C-3), 148.3 (C-4''), 145.8 (C-6), 135.9 (C-4), 134.5–127.3 (2Ph). Anal. Calcd for $\text{C}_{20}\text{H}_{13}\text{N}_5\text{OS}$ (371.4): C, 64.68; H, 3.53; N, 18.86. Found: C, 64.50; H, 3.43; N, 18.70.

General procedure for the synthesis of 7-(arylideneamino)-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-c]pyridazin-8(7H)-one derivatives (8a–c)

A mixture of compound **7** (1.0 g, 2.6 mmol) and the appropriate aldehyde, namely benzaldehyde, *p*-methoxybenzaldehyde, and *p*-nitrobenzaldehyde (2.6 mmol), was refluxed in ethanol (20 mL) for 4 h. The solvent was evaporated under reduced pressure, and the residue was triturated with diethyl ether (20 mL). The separated solid was filtered, dried, and recrystallized from ethanol to give **8a–c**.

7-(Benzylideneamino)-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-c]pyridazin-8(7H)-one (8a)

Brown crystals; yield 81.3 %; mp 205–207 °C; IR (KBr, cm^{-1}): 3056 (CH_{arom}), 1687 (C=O), 1630, 1620 (C=N); MS (m/z , %): 459 [M^+ , 49.09 %], 357 [$\text{M}^+ - \text{PhCN}$, 56.36 %, F₁], 317 [F₁-NCO, 69.09 %, F₂]; $^1\text{H-NMR}$ (DMSO- d_6): δ (ppm) = 9.1 (s, 1H, N = CHPh), 8.2 (s, 1H, H-6), 7.89–7.42 (m, 15H, 3Ph); $^{13}\text{C-NMR}$ (DMSO- d_6): δ (ppm): 162.5 (C-9'), 161.5 (C=O), 155.5 (C-3), 153.3 (CH=NPh), 148.3 (C-4''), 146.9 (C-6), 136.9 (C-4), 133.7–127.5 (3Ph). Anal. Calcd for $\text{C}_{27}\text{H}_{17}\text{N}_5\text{OS}$ (459.5):

C, 70.57; H, 3.73; N, 15.24. Found: C, 70.40; H, 3.63; N, 15.10.

7-((4-Methoxybenzylidene)amino)-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-c]pyridazin-8(7H)-one (8b)

Brown crystals; yield 76.3 %; mp 170–172 °C; IR (KBr, cm^{-1}): 3054 (CH_{arom}), 2990 (CH_{aliph}), 1665 (C=O), 1630 (C=N), 1079 (OCH₃); MS (m/z , %): 489 [M^+ , 17.21 %], 458 [$\text{M}^+ - \text{OCH}_3$, 17.80 %, F₁], 384 [F₁-Ph, 18.40 %, F₂], 342 [F₂-CH₂N₂, 23.44 %, F₃], 288 [F₃-NCO, 22.55 %, F₄]; $^1\text{H-NMR}$ (DMSO- d_6): δ (ppm) = 9.1 (s, 1H, N=CHPh), 8.2 (s, 1H, H-6), 7.89–7.05 (m, 15H, 3Ph), 3.5 (s, 1H, CH₃); $^{13}\text{C-NMR}$ (DMSO- d_6): δ (ppm): 162.5 (C-9'), 161.9 (C-O), 160.9 (C=O), 155.5 (C-3), 153.1 (N=CHPh), 148.3 (C-4''), 145.8 (C-6), 135.9 (C-4), 133.7–114.5 (3Ph) 55 (CH₃). Anal. Calcd for $\text{C}_{28}\text{H}_{19}\text{N}_5\text{O}_2\text{S}$ (489.5): C, 68.70; H, 3.91; N, 14.31. Found: C, 68.55; H, 3.75; N, 14.21.

7-((4-Nitrobenzylidene)amino)-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-c]pyridazin-8(7H)-one (8c)

Brown crystals; yield 74.0 %; mp 125–127 °C; IR (KBr, cm^{-1}): 3056 (CH_{arom}), 1658 (C=O), 1519, 1437 (NO₂); MS (m/z , %): 504 [M^+ , 15.47 %], 460 [$\text{M}^+ - \text{NO}_2$, 21.07 %, F₁], 383 [F₁-Ph, 18.67 %, F₂], 341 [F₂-CH₂N₂, 16.80 %, F₃], 288 [F₃-NCO, 14.40 %, F₄], 260 [F₄-N₂, 19.47 %, F₅]; $^1\text{H-NMR}$ (DMSO- d_6): δ (ppm) = 9.01 (s, 1H, N = CHPh), 8.2 (s, 1H, H-6), 7.95–7.42 (m, 14H, 3Ph); $^{13}\text{C-NMR}$ (DMSO- d_6): δ (ppm): 162.3 (C-9'), 161.5 (C=O), 156.1 (C-3), 153.8 (N=CHPh), 159.8 (C-NO₂), 149.1 (C-4''), 146.1 (C-6), 136.7 (C-4), 129.7–124.5 (3Ph). Anal. Calcd for $\text{C}_{27}\text{H}_{16}\text{N}_6\text{O}_3\text{S}$ (504.5): C, 64.28; H, 3.20; N, 16.66. Found: C, 64.10; H, 3.06; N, 16.50.

General procedure for the preparation of 7-N-substituted 3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-c]pyridazin-8(7H)-one (9a–d)

To a solution of compound **2** (1.0 g, 2.9 mmol) in glacial acetic acid (10 mL), substituted amines (2.9 mmol) were added, the reaction mixture was refluxed for 8 h, cooled and the formed precipitate was filtered, washed with water, and recrystallized from appropriate solvent to give **9a–d**.

7-Benzyl-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-c]pyridazin-8(7H)-one (9a)

Yellow crystals from chloroform, yield 48.5 %; mp 283–285 °C. IR (KBr, cm^{-1}): 3058 (CH_{arom}), 2916 (CH_{aliph}), 1676 (C=O), 1597 (C=N); MS (m/z): 446 [M^+ , 2.67 %], 370 [$\text{M}^+ - \text{C}_6\text{H}_5$, 1.32 %, F₁], 341 [F₁-NCH₃,

1.69 %, F₂], 288 [F₂-N = CHCHO, 1.76 %, F₃]; ¹H-NMR (DMSO-*d*₆): δ (ppm) = 8.2 (*s*, 1H, H-6), 7.69–7.26 (*m*, 15H, 3Ph), 4.2 (*s*, 2H, CH₂Ph); ¹³C-NMR (DMSO-*d*₆): δ (ppm): 162.5 (C-9'), 160.3 (C = O), 156.5 (C-3), 147.3 (C-6), 136.9 (C-4), 135.7–126.5 (3Ph), 47.1 (CH₂Ph). Anal. Calcd for C₂₇H₁₈N₄OS (446.5): C, 72.63; H, 4.06; N, 12.55. Found: C, 72.48; H, 3.90; N, 12.41.

*7-(2-Chlorobenzyl)-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-8(7H)-one (9b)*

Yellow crystals from chloroform; yield 54.05 %; mp 275–277 °C; IR (KBr, cm⁻¹): 3060 (CH_{arom}), 2917 (CH_{aliph}), 1677 (C=O), 1597 (C=N); MS (*m/z*): 480 [M⁺, 0.89 %], 446 [M⁺-Cl, 0.17 %, F₁], 355 [F₁-PhCH₃, 0.58 %, F₂], 313 [F₂-NCO, 4.93 %, F₃], 287 [F₃-N₂, 0.01 %, F₄]; ¹H-NMR (DMSO-*d*₆): δ (ppm) = 8.3 (*s*, 1H, H-6), 7.81–7.26 (*m*, 14H, 3Ph), 4.91 (*s*, 2H, CH₂Ph); ¹³C-NMR (DMSO-*d*₆): δ (ppm): 163.1 (C-9'), 160.1 (C=O), 156.4 (C-3), 148.1 (C-6), 137.2 (C-4), 135.4–127.3 (3Ph), 42.3 (CH₂Ph). Anal. Calcd for C₂₇H₁₇ClN₄OS (480.9): C, 67.42; H, 3.56; N, 11.65. Found: C, 67.27; H, 3.40; N, 11.50.

*3,4-Diphenyl-7-(phenylamino)pyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-8(7H)-one (9c)*

Yellow crystals from chloroform; yield 57.8 %; mp 290–292 °C; IR (KBr, cm⁻¹): 3390 (NH), 3059 (CH_{arom}), 1677 (C=O), 1596 (C=N); MS (*m/z*, %): 447 [M⁺, 0.58 %], 370 [M⁺-Ph, 3.65 %, F₁], 342 [F₁-N₂, 0.45 %, F₂], 287 [F₂-NCO, 0.38 %, F₃], 260 [F₃-N₂, 1.15 %, F₄]; ¹H-NMR (DMSO-*d*₆): δ (ppm) = 8.4 (*s*, 1H, H-6), 7.81–6.5 (*m*, 15H, 3Ph), 4.3 (*s*, 1H, NH); ¹³C-NMR (DMSO-*d*₆): δ (ppm): 162.9 (C-9'), 159.9 (C=O), 155.9 (C-3), 147.9 (C-6), 136.89 (C-4), 135.4–127.0 (3Ph). Anal. Calcd for C₂₆H₁₇N₅OS (447.5): C, 69.78; H, 3.83; N, 15.65. Found: C, 69.63; H, 3.68; N, 15.52.

*7-(4-Hydroxyphenethyl)-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-8(7H)-one (9d)*

Yellow crystals from chloroform, yield 46.5 %; mp 296–298 °C; IR (KBr, cm⁻¹): 3425 (OH), 3058 (CH_{arom}), 2916 (CH_{aliph}), 1676 (C=O), 1597 (C=N); MS (*m/z*, %): 476 [M⁺, 0.27 %], 461 [M⁺-OH, 0.54 %, F₁], 384 [F₁-Ph, 0.90 %, F₂], 356 [F₂-CH₂CH₂, 6.81 %, F₃], 329 [F₃-CN, 0.72 %, F₄], 288 [F₄-NCO, 0.72 %, F₅]; ¹H-NMR (DMSO-*d*₆): δ (ppm) = 8.6 (*s*, 1H, H-6), 7.81–6.3 (*m*, 14H, 3Ph), 5.9 (*s*, 1H, OH), 3.5 (*t*, 2H, CH₂N), 2.9 (*t*, 2H, CH₂Ph); ¹³C-NMR (DMSO-*d*₆): δ (ppm): 162.5 (C-9'), 160.5 (C=O), 156.7 (C-3), 153.6 (C-O), 146.9 (C-6), 133.4–115.0 (3Ph), 48.2 (CH₂N), 40.1 (CH₂Ph). Anal.

Calcd for C₂₈H₂₀N₄O₂S (476.55): C, 70.57; H, 4.23; N, 11.76. Found: C, 70.41; H, 4.08; N, 11.60.

*General procedure for the preparation of 7-substituted 3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-8(7H)-one (11a–g)*

To a solution of compound **2** (1.0 g, 2.9 mmol) in glacial acetic acid (10 mL), N'-substituted 4-aminobenzenesulfonamides **10a–g** (2.9 mmol) were added, the reaction mixture was refluxed for 8 h, cooled and the formed precipitate was filtered, washed with water, dried, and recrystallized from appropriate solvent to give pure **11a–g**.

*4-(8-Oxo-3,4-diphenylpyrimido[4',5':4,5]thienof[2,3-*c*]pyridazin-7(8H)-yl)benzenesulfonamide (11a)*

Yellow crystals, yield 59.3 %; mp 180–182 °C; IR (KBr, cm⁻¹): 3390, 3150 (NH₂), 3054 (CH_{arom}), 1664 (C=O), 1566 (C=N), 1337, 1134 (SO₂); MS (*m/z*, %): 512 [M⁺ + 1, 4.56 %], 448 [M⁺-SO₂, 0.85 %, F₁], 432 [F₁-NH₂, 1.07 %, F₂], 356 [F₂-Ph, 0.35 %, F₃], 312 [F₃-NCO, 3.68 %, F₄]; ¹H-NMR (DMSO-*d*₆): δ (ppm) = 8.5 (*s*, 1H, H-6), 8.1–7.52 (*m*, 14H, 3Ph), 2.3 (*s*, 2H, NH₂); ¹³C-NMR (DMSO-*d*₆): δ (ppm): 162.4 (C-9'), 161.2 (C=O), 156.2 (C-3), 147.5 (C-6), 136.5 (C-S), 133.4–121.3 (3Ph). Anal. Calcd for C₂₆H₁₇N₅O₃S₂ (511.5): C, 61.04; H, 3.35; N, 13.69. Found: C, 60.90; H, 3.20; N, 13.50.

*4-(8-Oxo-3,4-diphenylpyrimido[4',5':4,5]thienof[2,3-*c*]pyridazin-7(8H)-yl)-N-phenylbenzene sulfonamide (11b)*

Yellow crystals from chloroform; yield 51.4 %, mp 207–209 °C; IR (KBr, cm⁻¹): 3115 (NH), 3061 (CH_{arom}), 1672 (C=O), 1592 (C=N), 1324, 1163 (SO₂); MS (*m/z*, %): 587 [M⁺, 0.03 %], 523 [M⁺-SO₂, 0.08 %, F₁], 432 [F₁-PhNH₂, 0.06 %, F₂], 313 [F₂-PhNCO, 0.05 %, F₃]; ¹H-NMR (DMSO-*d*₆): δ (ppm) = 10.2 (*s*, 1H, NH), 8.5 (*s*, 1H, H-6), 8.0–6.52 (*m*, 19H, 4Ph); ¹³C-NMR (DMSO-*d*₆): δ (ppm): 163.1 (C-9'), 159.2 (C=O), 155.7 (C-3), 146.6 (C-6), 133.4–119.3 (4Ph). Anal. Calcd for C₃₂H₂₁N₅O₃S₂ (587.6): C, 65.40; H, 3.60; N, 11.92. Found: C, 65.26; H, 3.44; N, 11.76.

*N-(4-Chlorophenyl)-4-(8-oxo-3,4-diphenylpyrimido[4',5':4,5]thienof[2,3-*c*]pyridazin-7(8H)-yl) benzenesulfonamide (11c)*

Yellow crystals from chloroform; yield 34.7 %, mp 235–237 °C; IR (KBr, cm⁻¹): 3259 (NH), 3062 (CH_{arom}), 1670 (C=O), 1592 (C=N), 1325, 1164 (SO₂); MS (*m/z*, %): 621 [M⁺, 1.34 %], 511 [M⁺-PhCl, 0.64 %, F₁], 448 [F₁-SO₂, 0.61 %, F₂], 356 [F₂-PhNH₂, 0.35 %, F₃]; ¹H-NMR (DMSO-*d*₆): δ (ppm) = 10.3 (*s*, 1H, NH), 8.4 (*s*, 1H, H-6),

7.8–7.22 (*m*, 18H, 4Ph); ^{13}C -NMR (DMSO- d_6): δ (ppm): 162.9 (C-9'), 158.9 (C=O), 156.2 (C-3), 145.9 (C-6), 134.1–122.3 (4Ph). Anal. Calcd for $\text{C}_{32}\text{H}_{20}\text{ClN}_5\text{O}_3\text{S}_2$ (621.1): C, 61.78; H, 3.24; N, 11.26. Found: C, 61.63; H, 3.10; N, 11.11.

*4-(8-Oxo-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-7(8H)-yl)-N-(*o*-tolyl)benzene sulfonamide (11d)*

Yellow crystals from acetic acid; yield 50.4 %, mp 295–297 °C; IR (KBr, cm^{-1}): 3130 (NH), 3057 (CH_{arom}), 2919 (CH_{aliph}), 1676 (C=O), 1596 (C=N), 1319, 1170 (SO_2); MS (m/z , %): 601 [M^+ , 8.54 %], 587 [M^+ – CH_3 , 5.92 %, F_1], 523 [F_1 – SO_2 , 1.52 %, F_2], 431 [F_2 –PhNH $_2$, 9.09 %, F_3], 312 [F_3 –PhNCO, 16.67 %, F_4], 284 [F_4 – N_2 , 5.37 %, F_5]; ^1H -NMR (DMSO- d_6): δ (ppm) = 10.1 (*s*, 1H, NH), δ 8.3 (*s*, 1H, H-6) δ 7.8–7.22 (*m*, 18H, 4Ph), δ 2.9 (*s*, 3H, CH_3); ^{13}C -NMR (DMSO- d_6): δ (ppm): 163.1 (C-9'), 157.9 (C=O), 155.8 (C-3), 147.1 (C-6), 131.1–126.3 (4Ph), 18.1 (CH_3). Anal. Calcd for $\text{C}_{33}\text{H}_{23}\text{N}_5\text{O}_3\text{S}_2$ (601.7): C, 65.87; H, 3.85; N, 11.64. Found: C, 65.72; H, 3.70; N, 11.50.

*4-(8-Oxo-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-7(8H)-yl)-N-(*m*-tolyl)benzene sulfonamide (11e)*

Yellow crystals from ethanol; yield 43.2 %, mp 296–298 °C; IR (KBr, cm^{-1}): 3145 (NH), 3058 (CH_{arom}), 2915 (CH_{aliph}), 1676 (C=O), 1596 (C=N), 1319, 1172 (SO_2); MS (m/z , %): 602 [M^+ + 1, 1.80 %], 587 [M^+ – CH_3 , 1.99 %, F_1], 495 [F_1 –PhNH $_2$, 0.38 %, F_2], 431 [F_2 – SO_2 , 0.26 %, F_3], 313 [F_3 –PhNCO, 1.90 %, F_4], 285 [F_4 – N_2 , 0.17 %, F_5]; ^1H -NMR (DMSO- d_6): δ (ppm) = 10.3 (*s*, 1H, NH), δ 8.2 (*s*, 1H, H-6) δ 8.8–6.45 (*m*, 18H, 4Ph), δ 2.85 (*s*, 3H, CH_3); ^{13}C -NMR (DMSO- d_6): δ (ppm): 163.1 (C-9'), 157.9 (C=O), 155.8 (C-3), 147.1 (C-6), 131.1–126.3 (4Ph), 22.3 (CH_3). Anal. Calcd for $\text{C}_{33}\text{H}_{23}\text{N}_5\text{O}_3\text{S}_2$ (601.7): C, 65.87; H, 3.85; N, 11.64. Found: C, 65.74; H, 3.75; N, 11.48.

*N-Benzyl-4-(8-oxo-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-7(8H)-yl)benzene sulfonamide (11f)*

Yellow crystals from ethanol; yield 35.9 %, mp 290–292 °C; IR (KBr, cm^{-1}): 3155 (NH), 3058 (CH_{arom}), 2916 (CH_{aliph}), 1677 (C=O), 1596 (C=N), 1318, 1173 (SO_2); MS (m/z , %): 602 [M^+ + 1, 3.85 %], 537 [M^+ – SO_2 , 6.24 %, F_1], 447 [F_1 –Ph CH_2 , 1.70 %, F_2], 356 [F_2 –PhNH $_2$, 1.80 %, F_3], 313 [F_3 –NCO, 1.98 %, F_4], 285 [F_4 – N_2 , 14.14 %, F_5]; ^1H -NMR (DMSO- d_6): δ (ppm) = 10.5 (*s*, 1H, NH), δ 8.4 (*s*, 1H, H-6) δ 7.68–7.35 (*m*, 19H, 4Ph), δ 3.38 (*s*, 2H, CH_2); ^{13}C -NMR (DMSO- d_6): δ (ppm): 163.1 (C-9'), 157.9 (C=O), 155.8 (C-3), 147.1 (C-6), 141.5–126.9 (4Ph), 45.3 (CH_2). Anal. Calcd for $\text{C}_{33}\text{H}_{23}\text{N}_5\text{O}_3\text{S}_2$ (601.7): C, 65.87; H, 3.85; N, 11.64. Found: C, 65.77; H, 3.72; N, 11.50.

*N'-(2,4-Dinitrophenyl)-4-(8-oxo-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-7(8H)-yl)benzenesulfonohydrazide (11g)*

Yellow crystals from ethanol; yield 37.5 %, mp 254–256 °C; IR (KBr, cm^{-1}): 3390, 3170 (2NH), 3059 (CH_{arom}), 1677 (C=O), 1596 (C=N), 1490, 1444 (NO_2), 1322, 1174 (SO_2); MS (m/z , %): 694 [M^+ + 2, 2.97 %], 604 [M^+ – NO_2 , 3.76 %, F_1], 511 [F_1 –PhNH $_2$, 1.03 %, F_2], 433 [F_2 – SO_2 , 3.84 %, F_3], 313 [F_3 –PhNCO, 4.34 %, F_4], 285 [F_4 – N_2 , 5.63 %, F_5]; ^1H -NMR (DMSO- d_6): δ (ppm) : 10.1 (*s*, 1H, NH), 8.2 (*s*, 1H, H-6), 8.68–7.15 (*m*, 17H, 4Ph), 3.38 (*s*, 2H, CH_2); ^{13}C -NMR (DMSO- d_6): δ (ppm): 162.8 (C-9'), 158.1 (C=O), 155.2 (C-3), 147.1 (C-6), 141.5–118.2 (4Ph). Anal. Calcd for $\text{C}_{32}\text{H}_{20}\text{N}_8\text{O}_7\text{S}_2$ (692.6): C, 55.49; H, 2.91; N, 16.18. Found: C, 55.34; H, 2.80; N, 16.03.

*Ethyl ((4-(8-oxo-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-7(8H)-yl)phenyl)sulfonyl) carbamate (12)*

A mixture of **11a** (1.0 g, 1.9 mmol), ethyl chloroformate (0.21 g, 1.9 mmol), and anhydrous potassium carbonate (2.0 g) in dry acetone (100 mL) was refluxed for 5 h. The solvent was removed under reduced pressure, the residue was dissolved in water (100 mL) and neutralized with acetic acid. The product separated out was filtered, washed with water, dried, and recrystallized from ethanol to give **12**. Yellow crystals, yield 70.1 %, mp 175–177 °C; IR (KBr, cm^{-1}): 3350 (NH), 3059 (CH_{arom}), 1721 (C=O, amide), 1670 (C=O, cyclic), 1600 (C=N), 1375, 1172 (SO_2); MS (m/z , %): 583 [M^+ , 27.20 %], 537 [M^+ – $\text{CH}_3\text{CH}_2\text{OH}$, 36.40 %, F_1], 432 [F_1 – SO_2NCO , 26.36 %, F_2], 356 [F_2 –Ph, 23.01 %, F_3], 330 [F_3 – N_2 , 6.69 %, F_4], 287 [F_4 –NCO, 22.59 %, F_5]; ^1H -NMR (DMSO- d_6): δ (ppm) : 10.26 (*s*, 1H, NH), 8.7 (*s*, 1H, H-6), 7.7–7.2 (*m*, 14H, 3Ph), 3.3 (*q*, 2H, CH_2), 2.07 (*t*, 3H, CH_3); ^{13}C -NMR (DMSO- d_6): δ (ppm): 163.8 (C-9'), 158.5 (2C=O), 156.2 (C-3), 148.1 (C-6), 140.5–121.2 (3Ph), 63.5 (CH_2), 15.8 (CH_3). Anal. Calcd for $\text{C}_{29}\text{H}_{21}\text{N}_5\text{O}_5\text{S}_2$ (583.64): C, 59.68; H, 3.63; N, 12.00. Found: C, 59.50; H, 3.47; N, 11.85.

*General procedure for the preparation of substituted 4-(8-oxo-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-7(8H)-yl)benzenesulfonylurea (13a–e)*

To a solution of **12** (1.0 g, 1.7 mmol) in boiling toluene (30 mL), the desired primary amines were added (1.7 mmol) dropwise. The mixture was subsequently refluxed for further 6 h, and the solvent was evaporated. The residue was washed with diethyl ether and recrystallized from ethanol.

N-(Benzylcarbamoyl)-4-(8-oxo-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-7(8*H*)-yl)benzenesulfonamide (**13a**)

Yellow crystals, yield 63.6 %, mp 177–179 °C; IR (KBr, cm^{-1}): 3351, 3102 (2NH), 3055 (CH_{arom}), 2923 (CH_{aliph}), 1725 (cyclic C=O), 1646 (amide C=O), 1605 (C=N), 1333, 1140 (SO_2); MS (m/z , %): 643 [$\text{M}^+ - 1$, 0.46 %], 581 [$\text{M}^+ - \text{SO}_2$, 0.44 %, F_1], 490 [$\text{F}_1 - \text{PhCH}_2$, 0.66 %, F_2], 431 [$\text{F}_2 - \text{NHCONH}$, 0.55 %, F_3], 356 [$\text{F}_3 - \text{Ph}$, 0.66 %, F_4]; $^1\text{H-NMR}$ (DMSO- d_6): δ (ppm): 10.2 (*s*, 2H, NHCONH), 8.4 (*s*, 1H, H-6), 8.1–7.23 (*m*, 19H, 3Ph), 4.3 (*s*, 2H, CH_2); $^{13}\text{C-NMR}$ (DMSO- d_6): δ (ppm): 163.2 (C-9'), 161.8 (C=O, amide), 157.5 (C=O, cyclic), 156.9 (C-3), 147.1 (C-6), 140.5–126.2 (4Ph), 45.5 (CH_2). Anal. Calcd for $\text{C}_{34}\text{H}_{24}\text{N}_6\text{O}_4\text{S}_2$ (644.72): C, 63.34; H, 3.75; N, 13.04. Found: C, 63.19; H, 3.59; N, 12.88.

N-((2-Chlorobenzyl)carbamoyl)-4-(8-oxo-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-7(8*H*)-yl)benzenesulfonamide (**13b**)

Yellow crystals, yield 60.3 %, mp 168–170 °C; IR (KBr, cm^{-1}): 3341, 3190 (2NH), 3057 (CH_{arom}), 2981 (CH_{aliph}), 1720 (cyclic C=O), 1675 (amide C=O), 1603 (C=N), 1366, 1149 (SO_2); MS (m/z , %): 679 [M^+ , 20 %], 567 [$\text{M}^+ - \text{PhCl}$, 13.84 %, F_1], 511 [$\text{F}_1 - \text{CH}_3\text{NCO}$, 13.84 %, F_2], 431 [$\text{F}_2 - \text{SO}_2\text{NH}_2$, 5.25 %, F_3], 404 [$\text{F}_3 - \text{N}_2$, 10.26 %, F_4]; $^1\text{H-NMR}$ (DMSO- d_6): δ (ppm): 10.2 (*s*, 2H, NHCONH), 8.4 (*s*, 1H, H-6), 8.1–7.23 (*m*, 18H, 4Ph), 4.5 (*s*, 2H, CH_2); $^{13}\text{C-NMR}$ (DMSO- d_6): δ (ppm): 163.2 (C-9'), 161.4 (C=O, amide), 157.1 (C=O, cyclic), 156.9 (C-3), 147.1 (C-6), 142.5–126.6 (4Ph), 43.5 (CH_2). Anal. Calcd for $\text{C}_{34}\text{H}_{23}\text{ClN}_6\text{O}_4\text{S}_2$ (679.17): C, 60.13; H, 5.22; N, 12.37. Found: C, 60.00; H, 3.25; N, 12.20.

4-(8-Oxo-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-7(8*H*)-yl)-*N*-(*o*-tolylcarbamoyl) benzenesulfonamide (**13c**)

Yellow crystals, yield 54.5 %, mp 125–127 °C; IR (KBr, cm^{-1}): 3344, 3280 (2NH), 3057 (CH_{arom}), 2980 (CH_{aliph}), 1720 (cyclic C=O), 1674 (amide C=O), 1599 (C=N), 1372, 1151 (SO_2); MS (m/z , %): 644 [M^+ , 30.0 %], 630 [$\text{M}^+ - \text{CH}_3$, 28.5 %, F_1], 554 [$\text{F}_1 - \text{Ph}$, 33.0 %, F_2], 431 [$\text{F}_2 - \text{SO}_2\text{NHCONH}$, 43.0 %, F_3], 315 [$\text{F}_3 - \text{PhNCO}$, 32.5 %, F_4]; $^1\text{H-NMR}$ (DMSO- d_6): δ (ppm): 10.1 (*s*, 2H, NHCONH), δ 8.4 (*s*, 1H, H-6), δ 8.1–7.4 (*m*, 18H, 4Ph), δ 3.2 (*s*, 3H, CH_3); $^{13}\text{C-NMR}$ (DMSO- d_6): δ (ppm): 163.1 (C-9'), 161.0 (C=O, amide), 157.2 (C=O, cyclic), 156.3 (C-3), 147.1 (C-6), 140.5–115.6 (4Ph), 18.5 (CH_3). Anal. Calcd for $\text{C}_{34}\text{H}_{24}\text{N}_6\text{O}_4\text{S}_2$ (644.7): C, 63.34; H, 3.75; N, 13.04. Found: C, 63.20; H, 3.62; N, 12.90.

4-(8-Oxo-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-7(8*H*)-yl)-*N*-(*m*-tolylcarbamoyl) benzenesulfonamide (**13d**)

Yellow crystals, yield 63.6 %, mp 130–132 °C; IR (KBr, cm^{-1}): 3343, 3275 (2NH), 3056 (CH_{arom}), 2980 (CH_{aliph}), 1720 (cyclic C=O), 1674 (amide C=O), 1602 (C=N), 1371, 1151 (SO_2); MS (m/z , %): 644 [M^+ , 7.51 %], 631 [$\text{M}^+ - \text{CH}_3$, 5.20 %, F_1], 554 [$\text{F}_1 - \text{Ph}$, 7.80 %, F_2], 496 [$\text{F}_2 - \text{NHCONH}$, 0.19 %, F_3], 355 [$\text{F}_3 - \text{PhSO}_2$, 5.49 %, F_4], 330 [$\text{F}_4 - \text{N}_2$, 5.0 %, F_5]; $^1\text{H-NMR}$ (DMSO- d_6): δ (ppm): 10.1 (*s*, 2H, NHCONH), 8.4 (*s*, 1H, H-6), 8.1–7.4 (*m*, 18H, 4Ph), 2.9 (*s*, 3H, CH_3); $^{13}\text{C-NMR}$ (DMSO- d_6): δ (ppm): 163.1 (C-9'), 161.0 (C=O, amide), 157.2 (C=O, cyclic), 156.3 (C-3), 147.1 (C-6), 140.5–115.6 (4Ph), 26.5 (CH_3). Anal. Calcd for $\text{C}_{34}\text{H}_{24}\text{N}_6\text{O}_4\text{S}_2$ (644.7): C, 63.34; H, 3.75; N, 13.04. Found: C, 63.18; H, 3.60; N, 12.88.

N-((4-Chlorophenyl)carbamoyl)-4-(8-oxo-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-7(8*H*)-yl)benzenesulfonamide (**13e**)

Yellow crystals, yield 61.9 %, mp 115–117 °C; IR (KBr, cm^{-1}): 3351, 3290 (2NH), 3056 (CH_{arom}), 1720 (cyclic C=O), 1676 (amide C=O), 1596 (C=N), 1372, 1153 (SO_2); MS (m/z , %): 665 [M^+ , 0.14 %], 553 [$\text{M}^+ - \text{C}_6\text{H}_4\text{Cl}$, 0.19 %, F_1], 495 [$\text{F}_1 - \text{NHCONH}$, 0.31 %, F_2], 432 [$\text{F}_2 - \text{SO}_2$, 0.18 %, F_3], 315 [$\text{F}_3 - \text{PhNCO}$, 0.88 %, F_4], 287 [$\text{F}_4 - \text{N}_2$, 5.83 %, F_5]; $^1\text{H-NMR}$ (DMSO- d_6): δ (ppm): 10.6 (*s*, 2H, NHCONH), 8.5 (*s*, 1H, H-6), 8.4–7.4 (*m*, 18H, 4Ph); $^{13}\text{C-NMR}$ (DMSO- d_6): δ (ppm): 163.1 (C-9'), 161.0 (C=O, amide), 157.2 (C=O, cyclic), 156.3 (C-3), 147.1 (C-6), 140.5–120.6 (4Ph). Anal. Calcd for $\text{C}_{33}\text{H}_{21}\text{ClN}_6\text{O}_4\text{S}_2$ (665.1): C, 59.59; H, 3.18; N, 12.63. Found: C, 59.41; H, 3.01; N, 12.50.

Results and discussion

The condensation of ethyl 5-amino-3,4-diphenylthieno[2,3-*c*]pyridazine-6-carboxylate **1** with triethyl orthoformate in the presence of acetic anhydride as a catalyst give the corresponding ethoxymethyleneamino intermediate **2**. This was reacted directly without purification. The intermediate **2** was allowed to react with ammonium hydroxide at 70 °C affording the 3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-8(7*H*)-one **3** in a good yield. The structure of compound **3** was proved by its infrared, mass spectrum, and elemental analysis. The IR spectrum showed absorption bands at 3,165 cm^{-1} corresponding to NH, 1,655 cm^{-1} corresponding to C=O.

Heating compound **3** with phosphoryl chloride gave the corresponding 8-chloro derivative **4** in a good yield. Its

structure was proved by elemental analysis and spectral data, IR spectrum showed absorption band at $1,604\text{ cm}^{-1}$ corresponding to $\text{C}=\text{N}$, $1,071\text{ cm}^{-1}$ corresponding to $\text{C}-\text{Cl}$, and there are no absorption bands in the carbonyl region.


Reaction of 8-chloro derivative **4** with sodium azide in ethanol at refluxing temperature afforded 7,8-diphenyltetrazolo[1'',5'':1',6']pyrimido[4',5':4,5]thieno[2,3-*c*]pyridazine **4**, wherein 8-azido derivative was formed at the first step, then intramolecular cyclization to the tetrazolo derivative **4** occurred immediately. The predominant existence of the tetrazolo derivative **5** was supported by infrared spectral data, which exhibited no absorption bands around $2,200\text{ cm}^{-1}$ due to azido group, and there is absorption bands at $1,635\text{ cm}^{-1}$ corresponding to $\text{C}=\text{N}$. The 8-chloro derivative **4** on treatment with thiourea in absolute ethanol gave thiouronium salt which on hydrolysis with 2.5 N sodium hydroxide followed by acidification with hydrochloric acid (pH 2) gave 3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazine-8(7*H*)-thione **6** in 48 % yield. Structure of compound **6** was confirmed by its elemental analysis and spectral data. The IR spectrum showed absorption bands at $3,390\text{ cm}^{-1}$ corresponding to NH , $1,665\text{ cm}^{-1}$ corresponding to $\text{C}=\text{N}$, $1,531\text{ cm}^{-1}$ corresponding to $\text{C}=\text{C}$ and $1,194\text{ cm}^{-1}$ corresponding to $\text{C}=\text{S}$ (Scheme 1).

When the ethoxymethyleneamino derivative **2** was heated with hydrazine hydrate in acetic acid at refluxing temperature, afforded 7-amino-3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-8(7*H*)-one **7**. The assignment of structure of **7** was


based on an analytical and spectral data. The IR spectrum showed the presence of NH_2 group at $3,414$ and $3,150\text{ cm}^{-1}$, carbonyl group at $1,676\text{ cm}^{-1}$, and $\text{C}=\text{N}$ at $1,594\text{ cm}^{-1}$. Mechanistically, the formation of tricyclic compound **7** from **2** and hydrazine hydrate involved the initial formation of acid hydrazide which undergoes immediate intramolecular nucleophilic attack with elimination of ethanol molecule, forms 1,2,4-triazepine derivative **I**, which, as a result of transfer of the hydrogen atom from NH group to the oxygen atom, forms a hybrid **II**. The hybrid, following a translocation of the hydrogen atom from the nitrogen atom at position 3, changes into a transient structure **III**, whereas at position 3, an electron is still present as a result of hydrogen bonding accompanying the nonbonding pair of electrons of the nitrogen atom. That strongly electronegative nitrogen atom, in the reaction of intermolecular nucleophilic rearrangement, forms a link with the carbonyl carbon atom, releasing the $\text{C}-\text{N}$ bond. Structure **IV**, formed as result of that rearrangement, is not stable and, after translocation of the hydrogen atom from the carbonyl oxygen atom, transforms into compound **7** which is the product of this reaction chain (Scheme 2).

Alternatively, compound **7** was obtained upon heating of 5-amino-3,4-diphenylthieno[2,3-*c*]pyridazine-6-carbohy-drazide in dimethyl formamide as previously reported (Deeb and El-Abbasy, 2006). Then, condensation of 7-amino derivative **7** with aromatic aldehydes namely benzaldehyde, *p*-methoxybenzaldehyde, and *p*-nitrobenzaldehyde was carried out in (1:1) molar ratio with

Scheme 1 Synthesis of derivatives **1**, **2**, **3**, **4**, **5**, and **6**. Reagents and conditions *i* $\text{CH}(\text{OEt})_3/\text{Ac}_2\text{O}/\text{reflux}$, *ii* NH_4OH , *iii* $\text{POCl}_3/\text{reflux}$, *iv* NaN_3/EtOH , *v* $\text{NH}_2\text{CSNH}_2/\text{EtOH}$, NaOH , and then HCl



Scheme 2 .



elimination of water producing 7-arylideneamino derivatives **8a–c**. The structures of compounds **8a–c** were supported by their elemental analysis and spectral data. IR spectrum revealed the presence of absorption bands at $3,056\text{--}3,054\text{ cm}^{-1}$ due to CH_{arom} , $1,687\text{--}1,665\text{ cm}^{-1}$ corresponding to carbonyl group, and $1,630\text{--}1,620\text{ cm}^{-1}$ corresponding to $C=N$, further more IR spectrum of compound **8b** showed the presence of CH_{aliph} at $2,990\text{ cm}^{-1}$ and OCH_3 at $1,079\text{ cm}^{-1}$. Also, IR spectrum of compound **8c** showed the presence NO_2 at $1,519, 1,437\text{ cm}^{-1}$.

Since the primary amino group when is directly attached to a nitrogen of the heteroaromatic nucleus, an *N*-diazonium ion is generated as an intermediate which decomposes with ultimate deamination and formation of dinitrogen monoxide (Doyle *et al.*, 1974). It was of interest that the reaction of 7-amino derivative **7** with nitrous acid yields the anticipated 3,4-diphenylpyrimido[4',5':4,5]thieno[2,3-*c*]pyridazin-8(7*H*)-one **3**. Compound **3** was identical (mp, mixed mp, and superimposable IR) with an authentic sample synthesized in this work from 5-ethoxymethyleneamino derivative **2** which underwent smooth cyclization to **3** in the presence of ammonium hydroxide (Scheme 3).


Upon treatment of 5-ethoxymethyleneamino derivative **2** with amines such as benzyl amine, *o*-chlorobenzyl amine, tyramine, and phenylhydrazine, finally afforded 7-*N*-substituted pyrimidothienopyridazines **9a–d**. The infrared spectra of **9a–d** revealed the presence of absorption bands at 3425 cm^{-1} due to OH, $3,390\text{ cm}^{-1}$ corresponding to NH, $3,060\text{--}3,058\text{ cm}^{-1}$ corresponding to CH_{arom} , $2,917\text{--}2,916\text{ cm}^{-1}$ corresponding to CH_{aliph} , $1,677\text{--}1,676\text{ cm}^{-1}$ corresponding to $C=O$, and

absorption bands at $1,597\text{--}1,596\text{ cm}^{-1}$ corresponding to $C=N$.


The *N'*-(un)substituted 4-aminobenzenesulfonamides **10** were prepared using a previously described method (Vogel *et al.*, 1980). The nucleophilic substitution of the 4-amino group of **10** with 5-ethoxymethyleneamino-6-carboxylate **2** yielded the corresponding 7-*N*-substituted pyrimidothienopyridazines **11a–g**. The structure of the synthesized compounds was established on the basis of their IR, 1H -NMR, and mass spectral studies. The infrared spectra of **11a–g** showed absorption bands at $3,390\text{--}3,115\text{ cm}^{-1}$ corresponding to NH groups, $3,062\text{--}3,054\text{ cm}^{-1}$ corresponding to CH_{arom} , $1,676\text{--}1,664\text{ cm}^{-1}$ corresponding to $C=O$, $1,592\text{--}1,566\text{ cm}^{-1}$ corresponding to $C=N$ and bands at $1,337\text{--}1,324$, and $1,170\text{--}1,134\text{ cm}^{-1}$ corresponding to the symmetrical and asymmetrical vibrations of the SO_2 group. The 1H -NMR spectrum of **11c** showed signals at δ (ppm) = 10.3 corresponding to (SO_2NH) and at $\delta = 8.4$ corresponding to (H-6). Furthermore, the 1H -NMR spectrum of **11f** showed signals at δ 10.5 corresponding to (SO_2NH), at $\delta = 8.4$ corresponding to (H-6) and at $\delta = 3.38$ corresponding to (CH_2) (Scheme 4).

On the other hand, we have prepared the interesting sulfonylurea derivatives starting from the 7-(4-sulfamoylphenyl)pyrimidothienopyridazine **11a** on treatment with ethyl chloroformate in refluxing acetone containing anhydrous potassium carbonate yielded ethyl carbamate derivative **12**. The resulting carbamate was subsequently condensed with different substituted amines such as benzyl amine, *o*-chlorobenzyl amine, *o*-toluidine, *m*-toluidine, and *p*-chloroaniline to give novel benzene sulfonylurea


Scheme 3 Synthesis of derivatives **7** and **8a-c**.
Reagents and conditions
i $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O} / \text{AcOH} / \text{reflux}$, *ii* $\text{ArCHO} / \text{EtOH} / \text{reflux}$, *iii* $\text{HNO}_2 / \text{HCl}$



Scheme 4 Synthesis of derivatives **9a-d** and **11a-g**.
Reagents and conditions
i $\text{R-NH}_2 / \text{AcOH} / \text{reflux}$, *ii*




(**10a-g**), $\text{AcOH} / \text{reflux}$



derivatives **13a-e**. The structures of compound **12** as well as the final products **13a-e** were confirmed on the basis of both analytical and spectroscopic data. The IR spectrum of

compound **12** showed absorption band at $3,350 \text{ cm}^{-1}$ corresponding to NH group, $3,059 \text{ cm}^{-1}$ corresponding to CH_{arom} , $1,721 \text{ cm}^{-1}$ corresponding to (cyclic C=O),



Scheme 5 Synthesis of derivatives **12** and **13a–e**. Reagents and conditions *i* ClCOOEt/K₂CO₃/Acetone/reflux, *ii* RNH₂/Toluene/reflux

Table 1 Antimicrobial activity of some synthesized compounds

Compound	<i>Micrococcus luteus</i>	<i>Staphylococcus aureus</i>	<i>Escherichia coli</i>	<i>Candida albicans</i>
11a	++++	++++	+++	+++
11b	++	++	+++	++++
11c	+	+	+++	+++
11d	++	++	+++	+++
11e	+	+	++	++++
11f	++	++	+++	+++
11g	+++	+++	+++	++
11f	++	++	+++	+++
DMF	–	–	–	–
Sulfadoxine	+++	+++	++	+++
Sulfadimidine	+++	+++	++	+++
Nystatin	–	–	–	++++

Values are mean inhibition zone (mm) of two replicates, 25–35 mm = +++++, 18–24 mm = +++, 11–16 mm = ++, ≤10 mm = +, – = negative inhibition

1,670 cm⁻¹ corresponding to (amide C=O), 1,600 cm⁻¹ corresponding to C=N and absorption band at 1,375, and 1,172 cm⁻¹ corresponding to the symmetrical and asymmetrical vibrations of the SO₂ group. The ¹H-NMR spectrum showed signals at δ (ppm) = 10.26 corresponding to (SO₂NH), and at δ = 3.3 and 2.07 corresponding to CH₂

and CH₃, respectively. The IR spectra of compounds **13a–e** showed absorption bands at 3,351–3,102 cm⁻¹ corresponding to NH groups, 3,057–3,055 cm⁻¹ corresponding to CH_{arom}, 2,980–2,923 cm⁻¹ corresponding to CH_{aliph}, 1,725–1,720 cm⁻¹ corresponding to (cyclic C=O), 1,674–1,646 cm⁻¹ corresponding to (amide C=O), 1,605–

1,599 cm^{-1} corresponding to $\text{C}=\text{N}$, and absorption bands at 1,372–1,333 and 1,151–1,140 cm^{-1} corresponding to the symmetrical and asymmetrical vibrations of the SO_2 groups (Scheme 5).

Antimicrobial activity

Applying the agar plate diffusion technique (Bauer *et al.*, 1966), the newly synthesized sulfonamide derivatives were screened in vitro for antimicrobial activity against Gram-positive bacteria (*S. aureus* and *M. luteus*), Gram-negative bacteria (*E. coli*), and fungi (*C. albicans*). In this method, a standard 5 mm diameter sterilized filter paper disc impregnated with the compounds (400 μL /0.1 mL of dimethylformamide) was placed on the agar plates which had previously been inoculated with the above organisms. The petri dishes were left at 4 °C for 2 h.; then the injected plates with bacteria were incubated at 37 ± 0.1 °C for 24 h., and those inoculated with fungi incubated at 25 ± 0.1 °C for 48 h. At the end of the period, diameter of inhibition zones was measured in mm; these studies were performed in two replicates. The screening results given in (Table 1) indicated that all the compounds exhibited antimicrobial activity against all the test organisms.

Conclusion

In summary, we have developed and synthesized novel derivatives of pyrimidothienopyridazine. Some of the target compounds bearing the sulfonamide group were evaluated for their antimicrobial activity, and the following was concluded: derivative **11a** has promising inhibitory activity against Gram-positive bacteria. Derivatives **11b** and **11e** have remarkable inhibitory activity against fungi. Rest of the compounds showed moderate to low activity against the examined micro-organisms.

References

Asif M, Singh A, Ratnakar L (2011) Antimicrobial agents: brief study of pyridazine derivatives against some pathogenic microorganisms. *J Pharm Res* 4(3):664–667

- Bauer AW, Kirby MDK, Sherris JC, Turck M (1966) Antibiotic susceptibility testing by standard single disc diffusion method. *Am J Clin Pathol* 45:493–496
- Butnariu RM, Caprosu MD, Bejan V, Mangalagiu II, Ungureanu M, Poiata A, Tuchilus C, Florescu M (2007) Pyridazine and phthalazine derivatives with potential antimicrobial activity. *J Heterocycl Chem* 44(5):1149–1152
- Chambhare RV, Khadse BG, Bobde AS (2003) Synthesis and preliminary evaluation of some N-[5-(2-furanyl)-2-methyl-4-oxo-4H-thieno[2,3-d]pyrimidin-3-yl]-carboxamide and 3-substituted-5-(2-furanyl)-2-methyl-3H-thieno[2,3-d]pyrimidin-4-ones as antimicrobial agents. *Euro J Med Chem* 38(1):89–100
- Connor EE (1998) Sulfonamide Antibiotics. *Prim Care Update Ob Gyns* 5(1):32–35
- Deeb A, El-Abbasy M (2006) Pyridazine derivatives and related compounds, part 20:1 synthesis of different heterocycles from 5-Aminothieno[2,3-c]pyridazine-6-carbohydrazide. *Phosphorus Sulfur Silicon* 181:397–404
- Deeb A, Said SA, Hamed MM, Yasin F (1990) Pyridazine derivatives and related compounds, part 1. Some reactions with 4-cyano-5,6-diphenyl-2,3-dihydropyridazine-3-one. *J Chin Chem Soc* 37:287–294
- Deeb A, El-Eraky W, El-Awdan S, Mahgoub S (2014) Pyridazine and its related compounds, Part 34: hypoglycemic and hypolipidemic activity of some novel condensed pyridazine sulfonamides. *Med Chem Res* 23:34–41
- Doyle MP, Kalmbacher JG, Wierenga W, Deboer JE (1974) Nitrosative cleavage of benzalazine and related aldehyde azines. Production, decomposition and trapping of iminodiazonium ions. *Tetrahedron Lett* 15(15):1455–1458
- Drochioiu G, Sunel V, Oniscu C, Basu C, Murariu M (2007) The breakdown of plant biostructure followed by amino acids determination. *Rom Biotechnol Lett* 6(2):155–165
- Han X, Hong YH, You Quan ZHU, Mao LIU, Bim ZX, Fang Zhong HU, Zheng YH (2010) Synthesis and herbicidal activities of novel 4-(3-trifluoromethylphenyl)-2H-pyridazin-3-one derivatives. *Sci China Chem* 53(1):157–166
- Hansch C, Sammes PG, Taylor JB (1990) *Comprehensive medicinal chemistry*. Pergamon Press, Oxford, pp 255–270
- Hanson PR, Probst DA, Robinson RE, Yau M (1999) Cyclic sulfonamides via the ring-closing metathesis reaction. *Tetrahedron Lett* 40:4761–4764
- Kandile NG, Mohamed MI, Zaky H, Mohamed HM (2009) Novel pyridazine derivatives: synthesis and antimicrobial activity evaluation. *Eur J Med Chem* 44(5):1989–1996
- Kleemann A, Engel J, Kutscher B, Reichert D (1999) *Pharmaceutical substance: syntheses, patents, applications*, 2nd edn. Thieme, Stuttgart
- Mangalagiu II (2011) Recent achievements in the chemistry of 1,2-diazines. *Curr Org Chem* 15(5):730–752
- Mantu D, Luca MC, Moldoveanu C, Zbancioc G, Mangalagiu II (2010) Synthesis and antituberculosis activity of some new pyridazine derivatives. Part II. *Eur Med Chem* 45(11):5164–5168
- Tucaliuc RB, Risca IM, Drochioiu G, Mangalagiu I (2008) Biological effect of some new pyridazine derivatives on wheat in germination experiments. *Rom Biotechnol Lett* 13(4):3837–3842
- Vogel AI, Furniss Brian S (1980) *Vogel's textbook of practical organic chemistry*, 4th edn. Longman Group Limited, London, p 651